Literature DB >> 30643940

Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer.

Linlin Wang1, Taotao Dong2, Bowen Xin3, Chongrui Xu3, Meiying Guo1,4, Huaqi Zhang1,5, Dagan Feng3, Xiuying Wang6, Jinming Yu7.   

Abstract

OBJECTIVES: To determine the integrative value of clinical, hematological, and computed tomography (CT) radiomic features in survival prediction for locally advanced non-small cell lung cancer (LA-NSCLC) patients.
METHODS: Radiomic features and clinical and hematological features of 118 LA-NSCLC cases were firstly extracted and analyzed in this study. Then, stable and prognostic radiomic features were automatically selected using the consensus clustering method with either Cox proportional hazard (CPH) model or random survival forest (RSF) analysis. Predictive radiomic, clinical, and hematological parameters were subsequently fitted into a final prognostic model using both the CPH model and the RSF model. A multimodality nomogram was then established from the fitting model and was cross-validated. Finally, calibration curves were generated with the predicted versus actual survival status.
RESULTS: Radiomic features selected by clustering combined with CPH were found to be more predictive, with a C-index of 0.699 in comparison to 0.648 by clustering combined with RSF. Based on multivariate CPH model, our integrative nomogram achieved a C-index of 0.792 and retained 0.743 in the cross-validation analysis, outperforming radiomic, clinical, or hematological model alone. The calibration curve showed agreement between predicted and actual values for the 1-year and 2-year survival prediction. Interestingly, the selected important radiomic features were significantly correlated with levels of platelet, platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) (p values all < 0.05).
CONCLUSIONS: The integrative nomogram incorporated CT radiomic, clinical, and hematological features improved survival prediction in LA-NSCLC patients, which would offer a feasible and practical reference for individualized management of these patients. KEY POINTS: • An integrative nomogram incorporated CT radiomic, clinical, and hematological features was constructed and cross-validated to predict prognosis of LA-NSCLC patients. • The integrative nomogram outperformed radiomic, clinical, or hematological model alone. • This nomogram has value to permit non-invasive, comprehensive, and dynamical evaluation of the phenotypes of LA-NSCLC and can provide a feasible and practical reference for individualized management of LA-NSCLC patients.

Entities:  

Keywords:  Nomogram; Non-small cell lung cancer; Prognosis; Radiomics

Mesh:

Substances:

Year:  2019        PMID: 30643940     DOI: 10.1007/s00330-018-5949-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  41 in total

1.  Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer.

Authors:  G Cox; R A Walker; A Andi; W P Steward; K J O'Byrne
Journal:  Lung Cancer       Date:  2000-09       Impact factor: 5.705

2.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

Authors:  Ping Yang; Mark S Allen; Marie C Aubry; Jason A Wampfler; Randolph S Marks; Eric S Edell; Stephen Thibodeau; Alex A Adjei; James Jett; Claude Deschamps
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

Review 3.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

Review 4.  The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.

Authors:  Roy M Bremnes; Khalid Al-Shibli; Tom Donnem; Rafael Sirera; Samer Al-Saad; Sigve Andersen; Helge Stenvold; Carlos Camps; Lill-Tove Busund
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

Review 5.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

6.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors:  Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

7.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 8.  Tumor associated macrophages and neutrophils in tumor progression.

Authors:  Maria R Galdiero; Cecilia Garlanda; Sébastien Jaillon; Gianni Marone; Alberto Mantovani
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

9.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Authors:  Nasser Hanna; Marcus Neubauer; Constantin Yiannoutsos; Ronald McGarry; James Arseneau; Rafat Ansari; Craig Reynolds; Ramaswamy Govindan; Anton Melnyk; William Fisher; Donald Richards; Daniel Bruetman; Thomas Anderson; Naveed Chowhan; Sreenivasa Nattam; Prasad Mantravadi; Cynthia Johnson; Tim Breen; Angela White; Lawrence Einhorn
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  18 in total

1.  A novel clinical signature predicts the survival of elderly patients with oral squamous cell carcinoma.

Authors:  Wenkai Zhou; Canbang Peng; Zheqi Liu; Wei Cao
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-30       Impact factor: 2.503

2.  Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer.

Authors:  Bin Yang; Chengxing Liu; Ren Wu; Jing Zhong; Ang Li; Lu Ma; Jian Zhong; Saisai Yin; Changsheng Zhou; Yingqian Ge; Xinwei Tao; Longjiang Zhang; Guangming Lu
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

3.  MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma.

Authors:  Wei Pei; Chen Wang; Hai Liao; Xiaobo Chen; Yunyun Wei; Xia Huang; Xueli Liang; Huayan Bao; Danke Su; Guanqiao Jin
Journal:  BMC Cancer       Date:  2022-07-06       Impact factor: 4.638

4.  Combining Radiomics and Blood Test Biomarkers to Predict the Response of Locally Advanced Rectal Cancer to Chemoradiation.

Authors:  Seung Hyuck Jeon; Changhoon Song; Eui Kyu Chie; Bohyoung Kim; Young Hoon Kim; Won Chang; Yoon Jin Lee; Joo-Hyun Chung; Jin Beom Chung; Keun-Wook Lee; Sung-Bum Kang; Jae-Sung Kim
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

5.  A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.

Authors:  Xingxing Zheng; Jingjing Shao; Linli Zhou; Li Wang; Yaqiong Ge; Gaoren Wang; Feng Feng
Journal:  Ther Innov Regul Sci       Date:  2021-10-26       Impact factor: 1.778

Review 6.  Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.

Authors:  Isabella Fornacon-Wood; Corinne Faivre-Finn; James P B O'Connor; Gareth J Price
Journal:  Lung Cancer       Date:  2020-06-02       Impact factor: 5.705

7.  Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations.

Authors:  Bin Yang; Hengshan Ji; Jing Zhong; Lu Ma; Jian Zhong; Hao Dong; Changsheng Zhou; Shaofeng Duan; Chaohui Zhu; Jiahe Tian; Longjiang Zhang; Feng Wang; Hong Zhu; Guangming Lu
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

8.  Machine-Learning-Derived Nomogram Based on 3D Radiomic Features and Clinical Factors Predicts Progression-Free Survival in Lung Adenocarcinoma.

Authors:  Guixue Liu; Zhihan Xu; Yaping Zhang; Beibei Jiang; Lu Zhang; Lingyun Wang; Geertruida H de Bock; Rozemarijn Vliegenthart; Xueqian Xie
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

9.  Prognostic Value of Pre-Treatment CT Radiomics and Clinical Factors for the Overall Survival of Advanced (IIIB-IV) Lung Adenocarcinoma Patients.

Authors:  Duo Hong; Lina Zhang; Ke Xu; Xiaoting Wan; Yan Guo
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

10.  Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma.

Authors:  Dong Xie; Ting-Ting Wang; Shu-Jung Huang; Jia-Jun Deng; Yi-Jiu Ren; Yang Yang; Jun-Qi Wu; Lei Zhang; Ke Fei; Xi-Wen Sun; Yun-Lang She; Chang Chen
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.